Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled heparin plus N-acetylcysteine versus N-acetylcysteine alone versus placebo in ICU patients with COVID-19
IRCT20201210049672N1Phase 3Completed
- Sponsor
- Vice-Chancellery for Research, Hormozgan University of Medical Sciences
- Start
- Mar 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Heparin + N-acetylcysteine, N-acetylcysteine alone and Placebo (3 arms). Primary endpoint: Duration of ICU stay. Started Mar 2022; status: completed.
02
Drugs
heparinacetylcysteine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20201210049672N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201210049672N1.